TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8945276

Group type: EXPERIMENTAL
Intervention: Sterile cartridge‐needle units (Carpuject)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional disposable syringes with multiple‐ and single‐dose vials
Number of subjects: 6
Study: 2886245

Group type: EXPERIMENTAL
Intervention: 10 mg famotidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at 9 PM only
Number of subjects: 10
Study: 29775687

Group type: EXPERIMENTAL
Intervention: Salmeterol (Sal)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (FF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LABA (Salmeterol or Formoterol)
Number of subjects: 45
Study: 28809789

Group type: EXPERIMENTAL
Intervention: G-Breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-Breakfast
Number of subjects: 0
Study: 24681850

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) with adaptive statistical iterative reconstruction (ASIR) blending ratios (0%, 30%, 50%, and 70%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard-dose computed tomography (SDCT)
Number of subjects: 79
Study: 23596142

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20921462

Group type: EXPERIMENTAL
Intervention: Panitumumab 6.0 mg/kg plus FOLFIRI
Number of subjects: 1186

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1186
Study: 18826749

Group type: EXPERIMENTAL
Intervention: Travoprost (a.m. dosing)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Latanoprost (a.m. dosing)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Travoprost (evening dosing)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Latanoprost (evening dosing)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 51
Study: 16980830

Group type: EXPERIMENTAL
Intervention: Intervention group (life skills intervention)
Number of subjects: 116
Study: 14585918

Group type: EXPERIMENTAL
Intervention: Oral valdecoxib 20 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily
Number of subjects: 0
Study: 10805622

Group type: EXPERIMENTAL
Intervention: Intervention group (AHA pamphlet + pharmacologic information + standardized counseling)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (AHA pamphlet only)
Number of subjects: 152
Study: 8614068

Group type: EXPERIMENTAL
Intervention: Sequential gradient intermittent pneumatic compression (SGIPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (phase I)
Number of subjects: 0
Study: 8184809

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study: 3115668

Group type: EXPERIMENTAL
Intervention: PETCO2 elevated to 50 mmHg during the test period
Number of subjects: 5

Group type: COMPARATOR
Intervention: PETCO2 kept at 40 mmHg during the test period
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Change in PETCO2 from 40 to 50 mmHg
Number of subjects: 5
Study: 30509397

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 28057075

Group type: EXPERIMENTAL
Intervention: Compensatory training plus metacognitive skills training (COMP-MST)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Compensatory training only (COMP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study: 24476829

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study: 22321131

Group type: EXPERIMENTAL
Intervention: Harm reduction focused school drug education program (10 lessons in year eight and 8 lessons in year nine)
Number of subjects: 1746

Group type: COMPARATOR
Intervention: Control group receiving the normal drug education provided in their schools
Number of subjects: 1746
Study: 21059712

Group type: EXPERIMENTAL
Intervention: Vapor rub (VR)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Petrolatum
Number of subjects: 138

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 138
Study: 17464140

Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow extended daily dialysis (SLEDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study: 15865489

Group type: EXPERIMENTAL
Intervention: Yoga group (169 women)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (166 women)
Number of subjects: 335
Study: 12200949

Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms with prilocaine 75 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (prilocaine 75 mg alone)
Number of subjects: 40
Study: 9683043

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) method
Number of subjects: 189

Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP) method
Number of subjects: 189
Study: 7508826

Group type: EXPERIMENTAL
Intervention: c7E3 Fab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3397523

Group type: EXPERIMENTAL
Intervention: Lofepramine 70 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lofepramine 140 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31785169

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DPDT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cryotherapy (control)
Number of subjects: 24
Study: 29462482

Group type: EXPERIMENTAL
Intervention: Adjuvant S-1 therapy
Number of subjects: 440

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 440
Study: 28169983

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative inspiratory muscle training (IMT) using a threshold load inspiratory muscle trainer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (preoperative education and postoperative routine physical therapy)
Number of subjects: 40
Study: 26314389

Group type: EXPERIMENTAL
Intervention: Budesonide (swallowed topical corticosteroids)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 23127920

Group type: EXPERIMENTAL
Intervention: CIDR-G of first use (new devices)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: CIDR-G of third use (previously used twice)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: CIDR-G of second use (previously used once)
Number of subjects: 319
Study: 21544559

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study: 18438876

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 58
Study: 16546678

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12697590

Group type: EXPERIMENTAL
Intervention: Remifentanil at 2 ng ml(‐1) (low)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil at 4 ng ml(‐1) (medium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil at 8 ng ml(‐1) (high)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil (high concentration group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol effect site concentration
Number of subjects: 60
Study: 10882619

Group type: EXPERIMENTAL
Intervention: IncAHI <21.5 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Duration of AHI >15.5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: IncAHI >21.5 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Duration of AHI <15.5 days
Number of subjects: 70
Study: 8936126

Group type: EXPERIMENTAL
Intervention: Glucose polymer sports drink (GPSD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1426295

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound (TRUS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Digital rectal examination (DRE)
Number of subjects: 15
Study: 2931421

Group type: EXPERIMENTAL
Intervention: Procaterol inhaled (10 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (administered with a pressurized metered-dose inhaler)
Number of subjects: 9
Study: 31563302

Group type: EXPERIMENTAL
Intervention: DAR score categories (low, low-intermediate, high-intermediate, high)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intervention duration
Number of subjects: 275
Study: 29450636

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CYC) 6 × 500 mg fortnightly
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (CYC) 6 × 750 mg/m2 four-weekly
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (CYC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide (CYC)
Number of subjects: 75
Study: 26826547

Group type: EXPERIMENTAL
Intervention: HantavaxTM (three-dose schedule at 0, 1, and 13 months)
Number of subjects: 226
Study: 24792102

Group type: EXPERIMENTAL
Intervention: 2.4 mm scleral tunnel incision
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2.4 mm clear corneal incision
Number of subjects: 64
Study: 22283848

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (4 g day⁻¹ for 15 days)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg single dose preceded by 15 days of placebo)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 19575740

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 (PEG), 3.45 g t.i.d. orally for 30 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18036064

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multiple daily insulin injections (MDI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 16
Study: 16059855

Group type: EXPERIMENTAL
Intervention: DynEx dynamometer
Number of subjects: 100
Study: 11973420

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (0.05 microg/kg/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide (ANP) (0.05 microg/kg/min)
Number of subjects: 14
Study: 10361110

Group type: EXPERIMENTAL
Intervention: Extended ATRA (5-day course before chemotherapy)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Extended ATRA
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Extended ATRA in patients with WBC < 10 x 10(9)/L
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: RT-PCR monitoring after third chemotherapy course
Number of subjects: 239
Study: 8729953

Group type: EXPERIMENTAL
Intervention: IL‐2 6 x 10(6) units/M2 IV three days a week for four weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: IL‐2 5 x 10(6) units/M2 IV plus B‐IFN 6 x 10(6) units/M2 IV three days a week for four weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: IL‐2
Number of subjects: 84

Group type: COMPARATOR
Intervention: IL‐2 + B‐IFN
Number of subjects: 84
Study: 1710823

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 6110915

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study: 30327841

Group type: EXPERIMENTAL
Intervention: iTBCT
Number of subjects: 172

Group type: COMPARATOR
Intervention: STWU
Number of subjects: 172

Group type: COMPARATOR
Intervention: iTBCT vs STWU
Number of subjects: 172
Study: 28705210

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the foot for 60 minutes daily for 3 days after surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine postoperative care (Control)
Number of subjects: 66
Study: 24977459

Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 2166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study: 24494292

Group type: EXPERIMENTAL
Intervention: Nursing intervention in warm needling moxibustion (observation group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine nursing in warm needling moxibustion (control group)
Number of subjects: 200
Study: 22338959

Group type: EXPERIMENTAL
Intervention: Plantar angle-stable plate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dorsomedial angle-stable plate
Number of subjects: 12
Study: 20144417

Group type: EXPERIMENTAL
Intervention: ADP-RM short-term risk analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ADP-RM medium-term risk management
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ADP-RM system
Number of subjects: 10
Study: 16986228

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 25 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily
Number of subjects: 0
Study: 14979508

Group type: EXPERIMENTAL
Intervention: Nurse-led outpatient management
Number of subjects: 74

Group type: COMPARATOR
Intervention: Paediatrician management
Number of subjects: 74
Study: 11169534

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9024115

Group type: EXPERIMENTAL
Intervention: Early postpartum discharge program with nursing care available by telephone or at home at 34 to 38 weeks' gestation and at < or = 48 hours and at 3, 5, and 10 days post partum
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Early postpartum discharge program
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard postpartum care with a stay of 48 to 72 hours
Number of subjects: 175
Study: 8329292

Group type: EXPERIMENTAL
Intervention: Cicaprost 5 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cicaprost 7.5 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cicaprost 10 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3012819

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: BM 13.177
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (both groups)
Number of subjects: 14
Study: 30772975

Group type: EXPERIMENTAL
Intervention: Loading dose group (300 mg clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose group (75 mg clopidogrel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loading dose group (CYP2C19*2 carriers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose group (CYP2C19*2 carriers)
Number of subjects: 0
Study: 29995359

Group type: EXPERIMENTAL
Intervention: Tianeptine 25-50 mg/d
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Escitalopram 5-10 mg/d
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 26893309

Group type: EXPERIMENTAL
Intervention: Soft tissue treatment (Astym) and eccentric exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eccentric exercise only
Number of subjects: 16
Study: 24796199

Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation with bone grafting and pedicle screw implanting in injured vertebra (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cross segment pedicle instrumentation with bone grafting in injured vertebra (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Short-segment pedicle screw instrumentation (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cross segment pedicle instrumentation (Group B)
Number of subjects: 40
Study: 23100429

Group type: EXPERIMENTAL
Intervention: First context manipulation with U-shaped object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second context manipulation with U-shaped object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudorandom sequence of context switches with U-shaped object
Number of subjects: 0
Study: 19875236

Group type: EXPERIMENTAL
Intervention: Subcutaneous pedicle island flap
Number of subjects: 40

Group type: COMPARATOR
Intervention: Superficial temporal artery island flap
Number of subjects: 40
Study: 17385968

Group type: EXPERIMENTAL
Intervention: Common cold prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiovascular disease prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral shopping prime
Number of subjects: 0
Study: 15750362

Group type: EXPERIMENTAL
Intervention: Qigong lessons for 20 minutes at least twice weekly over a period of 6 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 12150309

Group type: EXPERIMENTAL
Intervention: Fixed-dose warfarin
Number of subjects: 296

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin
Number of subjects: 296
Study: 10215274

Group type: EXPERIMENTAL
Intervention: Prior aspirin use
Number of subjects: 9461

Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 9461
Study: 8530644

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRHa, triptorelin) 0.1 mg s.c. injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Human chorionic gonadotrophin (HCG) 10,000 IU i.m. injection
Number of subjects: 48
Study: 2115755

Group type: EXPERIMENTAL
Intervention: Comprehensive postfall assessment (n = 79)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (n = 81)
Number of subjects: 160
Study: 320109

Group type: EXPERIMENTAL
Intervention: D-penicillamine (1-2 g daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prednisone (15 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 35
Study: 31159884

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 27745532

Group type: EXPERIMENTAL
Intervention: HUD‐VASH (housing subsidies and case management)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Case management only
Number of subjects: 460

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 460
Study: 26669544

Group type: COMPARATOR
Intervention: External Connection (EC) implants
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Internal Connection (IC) implants
Number of subjects: 200
Study: 23115085

Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of rifampicin (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study: 21787052

Group type: EXPERIMENTAL
Intervention: Helping to Overcome PTSD through Empowerment (HOPE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard Shelter Services (SSS)
Number of subjects: 70
Study: 18258749

Group type: EXPERIMENTAL
Intervention: Licabazepine 500 mg single dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Licabazepine 500 mg multiple doses (500 mg bid on days 3 to 6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Licabazepine 500 mg single dose under fasted conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Licabazepine 500 mg single dose under fed conditions
Number of subjects: 24
Study: 16239861

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (GCBT) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sertraline for 12 weeks
Number of subjects: 40
Study: 12407614

Group type: EXPERIMENTAL
Intervention: Oral amiodarone, 15 mg/kg, 4 hours after arrival in the intensive care unit, followed by 7 mg/kg/d until hospital discharge
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral amiodarone and Placebo
Number of subjects: 200
Study: 9924052

Group type: EXPERIMENTAL
Intervention: Nicotine patch for 5 months with nicotine nasal spray for 1 year
Number of subjects: 237

Group type: COMPARATOR
Intervention: Nicotine patch with placebo spray
Number of subjects: 237
Study: 7760092

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Relative Delta Power
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BIS at 1.25 MAC isoflurane
Number of subjects: 42

Group type: COMPARATOR
Intervention: Other EEG variables
Number of subjects: 42
Study: 2194901

Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance
Number of subjects: 43

Group type: COMPARATOR
Intervention: Blinded technique
Number of subjects: 43
Study: 7226565

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg intravenous)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standardized exercise tests without naloxone
Number of subjects: 10
Study: 31393378

Group type: EXPERIMENTAL
Intervention: elvitegravir (EVG)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: dolutegravir (DTG)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: raltegravir (RAL)
Number of subjects: 323

Group type: COMPARATOR
Intervention: first-line group
Number of subjects: 323

Group type: COMPARATOR
Intervention: switch group
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: dolutegravir (DTG) in switch group
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: elvitegravir (EVG) in switch group
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: raltegravir (RAL) in switch group
Number of subjects: 323
Study: 27106901

Group type: EXPERIMENTAL
Intervention: Cognitive training programme
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 321
Study: 25945826

Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 79

Group type: COMPARATOR
Intervention: System B
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 79